Literature DB >> 9130647

Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid.

S Zahn1, J Zwirner, H P Spengler, O Götze.   

Abstract

Two homologous high-affinity receptors for the chemoattractant interleukin-8, IL-8RA and IL-8RB, and one for the chemoattractant C5a (C5aR) have been cloned. These membrane proteins are members of the rhodopsin superfamily of G-protein coupled seven-transmembrane segment receptors. New monoclonal antibodies (mAb) directed against the deduced N-terminal sequences of the IL-8RA (mAb SE2) and IL-8RB (mAb HC2) were generated to determine the IL-8R expression on human blood leukocytes and two human myeloid cell lines. The C5aR expression was detected using the mAb W17/1. Approximately 107,000 C5aR, 55,000 IL-8RA, and 25,000 IL-8RB molecules per cell could be detected on human granulocytes by flow cytometric analysis. On peripheral blood monocytes, 42,000 C5aR molecules/cell and 3000 IL-8RB molecules/cell were expressed. However, we were unable to quantitate IL-8RA expression, which was detectable but below 2500 molecules per cell and thus outside the standard range for the quantitation of receptor molecules by flow cytometry. On AML-193 cells, only the IL-8RB was constitutively expressed, whereas on HL-60 cells, we could not detect expression of any of the three receptors. Vitamin D3 (250 ng/ml, 7 days), which has been shown to induce differentiation of AML-193 and HL-60 cells into the monocytic phenotype, led to an up-regulation of IL-8RB and C5aR in both cell lines in the absence of any expression of IL-8RA. In contrast, all-trans retinoic acid (0.1 microM, 7 days), which induces differentiation into the granulocytic phenotype, led to an up-regulation of IL-8RB in AML-193 cells and to an expression of IL-8RB and C5aR in HL-60 cells. Again, neither cell line expressed IL-8RA. These findings suggest that regulation of IL-8RA expression differs from that of its IL-8RB homolog and may be a late event in leukocyte maturation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130647     DOI: 10.1002/eji.1830270420

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.

Authors:  A Fayyazi; O Scheel; T Werfel; S Schweyer; M Oppermann; O Götze; H J Radzun; J Zwirner
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  Interleukin-8 and its receptor CXCR2 in atherosclerosis.

Authors:  W A Boisvert; L K Curtiss; R A Terkeltaub
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.

Authors:  J Zwirner; O Götze; G Begemann; A Kapp; K Kirchhoff; T Werfel
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

4.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.

Authors:  W A Boisvert; R Santiago; L K Curtiss; R A Terkeltaub
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

Review 5.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

6.  The Complement Cascade as a Mediator of Human Malignant Hematopoietic Cell Trafficking.

Authors:  Anna Lenkiewicz; Kamila Bujko; Katarzyna Brzezniakiewicz-Janus; Bing Xu; Mariusz Z Ratajczak
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

7.  Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1.

Authors:  A Abdelbaset-Ismail; S Borkowska-Rzeszotek; E Kubis; K Bujko; K Brzeźniakiewicz-Janus; L Bolkun; J Kloczko; M Moniuszko; G W Basak; W Wiktor-Jedrzejczak; M Z Ratajczak
Journal:  Leukemia       Date:  2016-07-25       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.